Annex Advisory Services 13F: Adds $34M to LLY Stake

Annex Advisory Services significantly boosted its stake in Eli Lilly and Company (NYSE: LLY) in a filing on October 16, 2026. The firm added 29,346 shares, bringing its total to 33,181 shares. This increase represents a 765.2% rise in its position, valued at approximately $38.4 million.

What Changed in Annex Advisory Services' Position

Annex Advisory Services raised its holdings in Eli Lilly from 3,835 shares to 33,181 shares, marking a substantial addition to its investment. The firm's latest position reflects a strong belief in the company's prospects in the healthcare sector.

Other Institutional Activity in Eli Lilly

Several other funds have adjusted their stakes in Eli Lilly recently. Lilly Endowment, Inc. reduced its holdings by 1,516,238 shares, ending with 90,376,978 shares valued at about $113.6 billion. In contrast, Blackrock Inc. increased its stake by 1,161,629 shares, totaling 67,540,400 shares worth around $84.9 billion. Vanguard Capital Management LLC slightly added to its position with 165,427 shares, bringing its total to 53,528,868 shares valued at approximately $67.3 billion. PNC Financial Services Group, Inc. saw a minimal decrease of 5,133 shares, totaling 51,322,720 shares worth about $64.5 billion, while State Street Corporation raised its stake by 605,376 shares, for a total of 36,215,754 shares valued at about $45.5 billion.

Eli Lilly and Company Stock Up 3.9%

As of October 16, 2026, Eli Lilly shares were recently trading around $1,255.32, which is above both the 50-day and 200-day moving averages by 6.5% and 16.3%, respectively. The stock is currently sitting just below its 52-week high of $1,292.65, reflecting strong momentum in the market.

Recent Earnings

Eli Lilly reported impressive financials with a trailing twelve-month revenue of about $79.7 billion and an EPS of $29.79. The company has seen a revenue growth of 47.7% year-over-year, which showcases its robust market performance. The next earnings report is scheduled for October 29, 2026.

Insider Buying and Selling at Eli Lilly and Company

Several insiders at Eli Lilly have been active in the market. Officer Ilya Yuffa sold 2,500 shares on June 10, 2026, at an average price of $1,150.77, totaling about $2.9 million. General Counsel Anat Hakim sold 5,000 shares on August 7, 2026, for approximately $5.95 million at an average of $1,190.00. Officer Donald A Zakrowski sold 2,000 shares on August 10, 2026, at $1,185.01, totaling around $2.4 million, while Officer Patrik Jonsson sold 6,500 shares on August 17, 2026, for about $7.6 million at an average price of $1,175.10.

Analysts Set New Price Targets

Analysts have remained bullish on Eli Lilly. On September 22, 2026, TD Cowen reiterated a Buy rating with a price target of $1,250. JP Morgan maintained its Overweight rating on September 28, 2026, increasing its target to $1,500 from $1,400. Morgan Stanley also kept its Overweight rating with a target of $1,430 on October 7, 2026, while Cantor Fitzgerald raised its target to $1,440 from $1,410 on October 8, 2026. RBC Capital reiterated an Outperform rating with a $1,500 target on October 12, 2026. The consensus recommendation stands at Buy, with a mean price target of $1,328.05 from 30 analyst opinions.

About Eli Lilly

Eli Lilly and Company is a major player in the healthcare sector, focusing on discovering, developing, and marketing pharmaceuticals across various regions, including the U.S., Europe, and Asia. Its strong performance and growth potential make it a significant entity in the drug manufacturing industry.

Bottom Line

Investors should watch for Eli Lilly's upcoming earnings report on October 29, 2026, and any further changes in institutional holdings. Keep in mind that this filing reflects holdings as of the reporting period and may not represent Annex Advisory Services' current position. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.